Pharmaceutical Technology Europe E-Alert

Pharmaceutical Technology E-Alert: Having trouble viewing this e-mail? Click here.

BLOG

EVENT CALENDAR

COLUMNS

WHITE PAPERS

THE MAGAZINE

27 February 2013

PRINT SUBSCRIBE

IN THIS ISSUE
• News
• Webcasts
• Events
• About Us

Roche/Genentech Win FDA Approval for Antibody-Drug Conjugate
FDA approved Roche’s antibody-drug conjugate, Kadcyla (trastuzumab emtansine or T-DM1), for the treatment of people with HER2-positive metastatic breast cancer. More...

Affymax and Takeda Recall All Lots of OMONTYS (peginesatide) Injection
Affymax and Takeda Pharmaceutical Company Limited have decided to voluntarily recall all lots of OMONTYS (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions. More...

Report Explores Future of Opioid Abuse-Resistant Formulations
The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight. More...

Merck and Samsung Bioepis Form Biosimilars Development and Commercialization Agreement
Merck and Samsung Bioepis have formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates. More...

EMA Seeks to Expand Collaboration on Orphan Medicines
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) is seeking to expand its international cooperation in 2013. More...

BARDA Continues to Support Protein Sciences’ Cell-Based Vaccine Programs
Protein Sciences announced that the Biomedical Advanced Research and Development Authority (BARDA) will continue to support the company’s influenza vaccines program. More...

Sanofi Invests EUR 44 Million in Genzyme Campus
Sanofi is investing EUR 44 million ($58.7 million) in Genzyme’s biotechnology campus in Waterford, Ireland. More...

Product Profiles

Avacta Analytical

Avacta Analytical, a leading provider of analytical services and technologies, has unveiled the Optim® 2 microvolume protein analysis and characterisation instrument. This compact and robust system combines the powerful protein characterisation capabilities of the original Optim 1000 instrument with a new, application-oriented software package designed to increase throughput and functionality.